137 related articles for article (PubMed ID: 12444974)
1. Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation.
Pintus G; Tadolini B; Posadino AM; Sanna B; Debidda M; Bennardini F; Sava G; Ventura C
Eur J Biochem; 2002 Dec; 269(23):5861-70. PubMed ID: 12444974
[TBL] [Abstract][Full Text] [Related]
2. The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway.
Sanna B; Debidda M; Pintus G; Tadolini B; Posadino AM; Bennardini F; Sava G; Ventura C
Arch Biochem Biophys; 2002 Jul; 403(2):209-18. PubMed ID: 12139970
[TBL] [Abstract][Full Text] [Related]
3. NAMI-A inhibits the PMA-induced ODC gene expression in ECV304 cells: involvement of PKC/Raf/Mek/ERK signalling pathway.
Debidda M; Sanna B; Cossu A; Posadino AM; Tadolini B; Ventura C; Pintus G
Int J Oncol; 2003 Aug; 23(2):477-82. PubMed ID: 12851698
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A.
Vacca A; Bruno M; Boccarelli A; Coluccia M; Ribatti D; Bergamo A; Garbisa S; Sartor L; Sava G
Br J Cancer; 2002 Mar; 86(6):993-8. PubMed ID: 11953835
[TBL] [Abstract][Full Text] [Related]
5. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
Pelillo C; Mollica H; Eble JA; Grosche J; Herzog L; Codan B; Sava G; Bergamo A
J Inorg Biochem; 2016 Jul; 160():225-35. PubMed ID: 26961176
[TBL] [Abstract][Full Text] [Related]
7. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
9. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
10. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
12. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling.
Wang Z; Jiang C; Ganther H; Lü J
Cancer Res; 2001 Oct; 61(19):7171-8. PubMed ID: 11585751
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.
Oszajca M; Collet G; Stochel G; Kieda C; Brindell M
Biometals; 2016 Dec; 29(6):1035-1046. PubMed ID: 27812766
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration.
Pukac L; Huangpu J; Karnovsky MJ
Exp Cell Res; 1998 Aug; 242(2):548-60. PubMed ID: 9683541
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.
Morbidelli L; Donnini S; Filippi S; Messori L; Piccioli F; Orioli P; Sava G; Ziche M
Br J Cancer; 2003 May; 88(9):1484-91. PubMed ID: 12778081
[TBL] [Abstract][Full Text] [Related]
17. CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.
Bergamo A; Delfino R; Casarsa C; Sava G
Anticancer Agents Med Chem; 2012 Oct; 12(8):949-58. PubMed ID: 22263785
[TBL] [Abstract][Full Text] [Related]
18. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.
Bergamo A; Zorzet S; Gava B; Sorc A; Alessio E; Iengo E; Sava G
Anticancer Drugs; 2000 Sep; 11(8):665-72. PubMed ID: 11081461
[TBL] [Abstract][Full Text] [Related]
19. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
20. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
